| 1 |
Miller DT, Adam MP, Aradhya S, et al. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet 2010;86:749-64.
DOI
|
| 2 |
Manning M, Hudgins LProfessional Practice and Guidelines Committee. Array-based technology and recommendations for utilization in medical genetics practice for detection of chromosomal abnormalities. Genet Med 2010;12:742-5.
DOI
|
| 3 |
Coulter ME, Miller DT, Harris DJ, et al. Chromosomal microarray testing influences medical management. Genet Med 2011;13:770-6.
DOI
|
| 4 |
Battaglia A, Doccini V, Bernardini L, et al. Confirmation of chromosomal microarray as a first-tier clinical diagnostic test for individuals with developmental delay, intellectual disability, autism spectrum disorders and dysmorphic features. Eur J Paediatr Neurol 2013;17:589-99.
DOI
|
| 5 |
Bejjani BA, Saleki R, Ballif BC, et al. Use of targeted array-based CGH for the clinical diagnosis of chromosomal imbalance: is less more? Am J Med Genet A 2005;134:259-67.
|
| 6 |
Barrett MT, Scheffer A, Ben-Dor A, et al. Comparative genomic hybridization using oligonucleotide microarrays and total genomic DNA. Proc Natl Acad Sci U S A 2004;101:17765-70.
DOI
|
| 7 |
Stankiewicz P, Beaudet AL. Use of array CGH in the evaluation of dysmorphology, malformations, developmental delay, and idiopathic mental retardation. Curr Opin Genet Dev 2007;17:182-92.
DOI
|
| 8 |
Keren B. The advantages of SNP arrays over CGH arrays. Mol Cytogenet 2014;7:I31.
DOI
|
| 9 |
Choi BG, Hwang SK, Kwon JE, Kim YH. Array comparative genomic hybridization as the first-line investigation for neonates with congenital heart disease: experience in a single tertiary center. Korean Circ J 2018;48:209-16.
DOI
|
webmaster
